Ford government decision is a step backward for investor protection


By Anita Anand

Globe and Mail September 25, 2018

The Ontario Securities Commission recently published a proposed rule banning certain commissions to dealers on mutual fund sales. The rule was not just Ontario’s initiative – it was a joint effort by members of the Canadian Securities Administrators (CSA), which consists of regulators from all provinces and territories. After months of discussions, which included the consideration of empirical data, the CSA finally agreed on the need to restrict certain commissions, with each of its members agreeing to implement the rule in its home province or territory.

Then, to the surprise of many, Ontario Minister of Finance Vic Fedeli expressed the government’s disagreement with the rule, ignoring the statutory process for making laws relating to the capital markets in this province. The Minister’s approach presents three problems. First, it undermines the rule-making process that is embodied in statute and has been the law for more than 20 years. Second, it fails to appreciate the important investor protection concerns that the CSA identified and sought to address. Third, it creates uncertainty in the capital markets, which the government of the day should be loath to do.

Prof. Trudo Lemmens co-authors "Disclosure of pharma payments to doctors is a good first step – but it’s not enough"

Thursday, September 28, 2017

In a commentary in the Globe and Mail, Prof. Trudo Lemmens and co-author Paul D. Thacker praise Ontario's initiative to require medical companies to disclose payments to health-care providers, but note other areas of commercial drug marketing that also need greater transparency ("Disclosure of pharma payments to doctors is a good first step – but it’s not enough," September 27, 2017.

Prof. Anand named to expert panel reviewing financial advisers and planners sector

Tuesday, April 28, 2015
headshot of Anita Anand

Prof. Anita Anand is one of four independent experts named to an Ontario panel to review the regulations relating to financial advisers and planners, provincial finance minister Charles Sousa announced April 27th.

The Pharmaceutical Industry’s Shift towards Niche Markets and ‘Personalized Medicine’: New Article Reports on Qualitative Study and Critically Analyzes Ethical and Regulatory Challenges

Reports abound of an apparent innovation crisis in the pharmaceutical sector, with some sources citing escalating drug development costs, declining new drug approvals, and an increasingly stringent regulatory environment. Concurrently, commentators refer to the death, or at least the decline, of the blockbuster model of drug development—where large, brand-name pharmaceutical companies rely on a portfolio of drugs that gross more than U.S. $1 billion per year—which has dominated the pharmaceutical sector for decades.

Decreasing the Data Deficit: Improving Canada's Drug Regulatory System

Decreasing the Data Deficit: Improving Canada’s Drug Regulatory System: Paper by Trudo Lemmens & Shannon Gibson now publicly available on SSRN.


Getting into UofT Law - JD Admissions

JD Admissions visits UofT Department of Criminology

JD AdmissionsGet the inside scoop on applying to our JD program directly from the Faculty of Law Admissions Office and hear from current law students. 

Learn about our whole-person admission process and how to improve your application to our JD program. 

Innovation Law & Policy Workshop: Rebecca Tushnet



Rebecca Tushnet

Georgetown University Law Center 

A Mask that Eats into the Face: Images and the Right of Publicity”


Wednesday, March 11, 2015

12:30 - 2pm

Solarium (Room FA2), Falconer Hall

Prof. Lisa Austin - "We can’t let phone companies determine our privacy rights"

Tuesday, May 6, 2014

In a commentary in The Globe and Mail, Prof. Lisa Austin, with Prof. Andrea Slane of the University of Ontario Institute of Technology, reveals the legal loophole that has allowed the Canadian government to access customer information from telecom providers without a warrant ("We can’t let phone companies determine our privacy rights," May 5, 2014).

Read the full commentary on The Globe and Mail website, or below.

Access to Pharmaceutical Data, Not Data Secrecy, is an Essential Component of Human Rights

Recent media reports rightly point to Canada’s abysmal record when it comes to transparency of pharmaceutical data; this notwithstanding numerous calls and recommendations for urgent action, including in a 2012 Standing Senate Committee on Social Affairs, Science and Technology Report. A recent announcement by Health Canada that it was publishing a ‘summary report’ of data about the controversial acne pill Diane-35 (6 months after it announced it would do so) does little to reassure that we are really catching up with other countries.